Body fluid biomarkers in multiple sclerosis

Manuel Comabella*, Xavier Montalban

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

206 Cites (Scopus)

Resum

Biomarkers can be thought of as multifaceted indicators of healthy status or of pathological disorders. The study of multiple sclerosis can benefit from the use of biomarkers because of the disease's inherent heterogeneity. Biomarkers in multiple sclerosis might assist with diagnosis, prediction of disease course, or identification of response outcome to treatments. Despite the need for biomarkers and extensife research to identify them, validation and clinical application of biomarkers is still an unmet need in multiple sclerosis, and large gaps remain between exploratory biomarkers proposed in many studies, validated biomarkers, and biomarkers that are integrated into routine clinical practice.

Idioma originalAnglès
Pàgines (de-a)113-126
Nombre de pàgines14
RevistaThe Lancet Neurology
Volum13
Número1
DOIs
Estat de la publicacióPublicada - de gen. 2014

Fingerprint

Navegar pels temes de recerca de 'Body fluid biomarkers in multiple sclerosis'. Junts formen un fingerprint únic.

Com citar-ho